What is Gen9bio?
Headquartered in San Jose, California, Gen9bio operates at the intersection of molecular biology and industrial-scale DNA production. The company specializes in the design and synthesis of DNA primers and advanced antibody reagents, including TK and DHH variants. By providing high-quality, custom-engineered genetic materials, Gen9bio serves as a critical infrastructure provider for laboratories, pharmaceutical developers, and diagnostic firms worldwide.
The company's market position is defined by its ability to streamline the complex workflows associated with DNA primer design. As the biotechnology industry continues to prioritize rapid prototyping and precision medicine, Gen9bio's technical capabilities offer a competitive advantage, enabling researchers to accelerate their discovery pipelines while maintaining rigorous quality standards.
How much funding has Gen9bio raised?
Gen9bio has raised a total of $50.4M across 6 funding rounds:
Private Equity
$500K
Debt
$2M
Series B
$1.6M
Debt
$395K
Private Equity
$21M
Series C
$25M
Private Equity (2009): $500K, investors not publicly disclosed
Debt (2010): $2M, investors not publicly disclosed
Series B (2011): $1.6M supported by Draper Fisher Jurvetson and PBM Capital Group
Debt (2012): $395K featuring Draper Fisher Jurvetson and PBM Capital Group
Private Equity (2013): $21M backed by Draper Fisher Jurvetson, PBM Capital Group, Agilent Technologies, and The Kraft Group
Series C (2014): $25M, investors not publicly disclosed
Key Investors in Gen9bio
Draper Fisher Jurvetson
A prominent venture capital firm with a global footprint, dedicated to providing capital and strategic support to extraordinary entrepreneurs across diverse technology sectors.
PBM Capital Group
An investment group with deep roots in the healthcare and consumer product sectors, focusing on companies that adhere to rigorous regulatory and quality standards.
Agilent Technologies
A global leader in life sciences and diagnostics, providing advanced instrumentation and services that empower laboratories to generate accurate insights and advance scientific innovation.
What's next for Gen9bio?
With the infusion of its latest capital, Gen9bio is well-positioned to expand its operational footprint and enhance its synthesis throughput. The strategic focus will likely shift toward optimizing its manufacturing processes to further reduce costs for end-users, thereby capturing a larger share of the burgeoning synthetic biology market. Furthermore, the involvement of high-profile investors suggests a potential pivot toward broader commercial applications, including large-scale pharmaceutical partnerships and the development of next-generation diagnostic tools. As the company matures, its ability to maintain technical superiority while scaling production will be the primary determinant of its long-term market leadership.
See full Gen9bio company page
